

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

She

1

1

Complete if Known

Application Number	10/663,407
Filing Date	September 15, 2003
First Named Inventor	Zavitz et al.
Art Unit	1648
Examiner Name	Unknown PARKER, JEFFREY
Attorney Docket Number	1907.04-1

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			
<i>J</i>		WO 02/094314	11/28/2002	Cohen et al.	


*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Application has been withdrawn if English language translation is attached.

8 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.72 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete If Known	
Sheet	2	of	5	Attorney Docket Number	1907.04-1

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
<i>JM</i>		ACCOLA et al., "Efficient Particle Production by Minimal Gag Constructs Which Retain the Carboxy-Terminal Domain of Human Immunodeficiency Virus Type 1 Capsid-p2 and a Late Assembly Domain", <i>Journal of Virology</i> , June 2000, 74(12):5395-5402.			
		ALEXANDER et al., "Unusual Polymorphisms in Human Immunodeficiency Virus Type 1 Associated with Nonprogressive Infection", <i>Journal of Virology</i> , May 2000, 74(9):4361-4376.			
		BABST et al., "Mammalian Tumor Susceptibility Gene 101 (TSG101) and the Yeast Homologue, Vps23p, Both Function in Late Endosomal Trafficking", <i>Traffic</i> , 2000, 1:248-258.			
		BISHOP et al., "TSG101/Mammalian VPS23 and Mammalian VPS28 Interact Directly and Are Recruited to VPS4-induced Endosomes", <i>The Journal of Biological Chemistry</i> , April 13, 2001, 276(15):11735-11742.			
		BUTKIEWICZ et al., "Virus-Specific Cofactor Requirement and Chimeric Hepatitis C Virus/GB Virus B Nonstructural Protein 3" <i>Journal of Virology</i> , May 2000, 74(9):4291-4301.			
		CARTER, "Tsg101: HIV-1's ticket to ride", <i>Trends in Microbiology</i> , May 2002, 10(5):203-205.			
		CRAVEN et al., "Late Domain Function Identified in the Vesicular Stomatitis Virus M Protein by Use of Rhabdovirus-Retrovirus Chimeras", <i>Journal of Virology</i> , April 1999, 73(4):3359-3365.			
		CRUMP et al., "Inhibition of the Interaction between Tyrosine-based Motifs and the Medium Chain Subunit of the AP-2 Adaptor Complex by Specific Tyrophostins", <i>The Journal of Biological Chemistry</i> , October 23, 1998, 273(43):28073-28077.			
		DEMIROV et al., "Overexpression of the N-Terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function", <i>PNAS</i> , January 22, 2002, 99(2):955-960.			
		DESAI et al., "Molecular cloning and primary nucleotide sequence analysis of a distinct human immunodeficiency virus isolate reveal significant divergence in its genomic sequences", <i>PNAS</i> , November 1986, 83(21):8380-8384.			
		DESCHAMBEAULT et al., "Polarized Human Immunodeficiency Virus Budding in Lymphocytes Involves a Tyrosine-Based Signal and Favors Cell-to-Cell Viral Transmission", <i>Journal of Virology</i> , June 1999, 73(6):5010-5017.			
		FARRAR et al., "Characterisation of a Series of Human Immunodeficiency Virus Isolates Derived Sequentially From a Single Patient", <i>Journal of Medical Virology</i> , 1991, 34:104-113.			
		GARNIER et al., "Identification of Retroviral Late Domains as Determinants of Particle Size", <i>Journal of Virology</i> , March 1999, 73(3):2309-2320.			
<i>↓</i>		GARRUS et al., "Tsg101 and the Vacuolar Protein Sorting Pathway Are Essential for HIV-1 Budding", <i>Cell</i> , October 5, 2001, 107:55-65.			

Examiner Signature		Date Considered
		02/17/07


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449A/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/663,407
(use as many sheets as necessary)				Filing Date	September 15, 2003
Sheet	3	of	5	First Named Inventor	Zavitz et al.
				Art Unit	1648-1648
				Examiner Name	Unknown PARKER, STEFFREY
				Attorney Docket Number	1907.04-1

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. T ²			
J		HARTY et al., "A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: Implications for filovirus budding", PNAS, December 5, 2000, 97(25):13871-13876.			
		HARTY et al., "A Proline-Rich Motif within the Matrix Protein of Vesicular Stomatitis Virus and Rabies Virus Interacts with WW Domains of Cellular Proteins: Implications for Viral Budding", Journal of Virology, April 1999, 73(4):2921-2929.			
		HARVEY et al., "Nedd4-like proteins: an emerging family of ubiquitin-protein ligases implicated in diverse cellular functions", Trends in Cell Biology, May 1999, 9:166-169.			
		HEINRICHS et al., "In vivo analysis of the functional domains of the Drosophila splicing regulator RBP1", 1997, PNAS, 94:115-120.			
		HUANG et al., "p6 ^{Gag} Is Required for Particle Production from Full-Length Human Immunodeficiency Virus Type 1 Molecular Clones Expressing Protease", Journal of Virology, November 1995, 69(11):6810-6818.			
		JAYAKAR et al., "Mutations in the PPPY Motif of Vesicular Stomatitis Virus Matrix Protein Reduce Virus Budding by Inhibiting a Late Step in Virion Release", Journal of Virology, November 2000, 74(21):9818-9827.			
		LEVIN et al., "Inhibition of Early and Late Events of the HIV-1 Replication Cycle by Cytoplasmic Fab Intrabodies against the Matrix Protein, p17", Molecular Medicine, February 1997, 3(2):96-110.			
		LUBAN, "HIV-1 and Ebola virus: The getaway driver nabbed", Nature Medicine, December 2001, 7(12):1278:1280.			
		MARTIN-SERRANO et al., "HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress", Nature Medicine, December 2001, 7(12):1313-1319.			
		MHASHILKAR et al., "Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies", The EMBO Journal, 1995, 14(7):1542-1551.			
		MYERS et al., "Tsg101, an Inactive Homologue of Ubiquitin Ligase E2, Interacts Specifically with Human Immunodeficiency Virus Type 2 Gag Polyprotein and Results in Increased Levels of Unubiquitinated Gag", Journal of Virology, November 2002, 76(22):11226-11235.			
		NCBI Entrez Protein Database Accession No.: AAB38034, December 5, 1996.			
		NCBI Entrez Protein Database Accession No.: AAB83138, November 6, 1997.			
↓		NCBI Entrez Protein Database Accession No.: AAB83216, November 6, 1997.			

Examiner Signature		Date Considered	02/11/07
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449A/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/663,407
				Filing Date	September 15, 2003
				First Named Inventor	Zavitz et al.
				Art Unit	1648
				Examiner Name	Unknown PARSONS, STEPHEN T
Sheet	4	of	5	Attorney Docket Number	1907.04-1

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
<i>J</i>		NCBI Entrez Protein Database Accession No.: AAB83821, November 6, 1997.				
		NCBI Entrez Protein Database Accession No.: AAD03232, January 6, 1999.				
		NCBI Entrez Protein Database Accession No.: AAD03240, January 6, 1999.				
		NCBI Entrez Protein Database Accession No.: AAD17020, June 1, 2001.				
		NCBI Entrez Protein Database Accession No.: AAF35354, February 23, 2000.				
		NCBI Entrez Protein Database Accession No.: CAB92786, September 20, 2000.				
		NCBI Entrez Protein Database Accession No.: P35962, July 15, 1998.				
		OTT et al., "Ubiquitin Is Covalently Attached to the p6 ^{Gag} Proteins of Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus and to the p12 ^{Gag} Protein of Moloney Murine Leukemia Virus", <i>Journal of Virology</i> , April 1998, 72(4):2962-2968.				
		PARENT et al., "Positionally Independent and Exchangeable Late Budding Functions of the Rous Sarcoma Virus and Human Immunodeficiency Virus Gag Proteins", <i>Journal of Virology</i> , September 1995, 69(9):5455-5460.				
		PATNAIK et al., "Ubiquitin is part of the retrovirus budding machinery", <i>PNAS</i> , November 21, 2000, 97(24):13069-13074.				
		PORNILLOS et al., Structure and functional interactions of the Tsg101 UEV domain", <i>The EMBO Journal</i> , 2002, 21(10):2397-2406.				
		PORNILLOS et al., "Structure of the Tsg101 UEV domain in complex with the PTAP motif of the HIV-1 p6 protein", <i>Nature Structural Biology</i> , November 2002, 9(11):812-817.				
		PUFFER et al., "Equine Infectious Anemia Virus Gag Polyprotein Late Domain Specifically Recruits Cellular AP-2 Adapter Protein Complexes during Virion Assembly", <i>Journal of Virology</i> , December 1998, 72(12):10218-10221.				
		PUFFER et al., "Equine Infectious Anemia Virus Utilizes a YXXL Motif within the Late Assembly Domain of the Gag p9 Protein", <i>Journal of Virology</i> , September 1997, 71(9):6541-6546.				
		ROSSI, "Therapeutic applications of catalytic antisense RNAs (ribozymes)", <i>CIBA Foundation Symposium</i> , 1997, 209:195-206.				
<i>↓</i>		SAVARINO et al., "The Biochemistry of Gene Therapy for AIDS", <i>Clin. Chem. Lab. Med.</i> , 1998, 36(4):205-210.				

Examiner Signature	<i>[Signature]</i>	Date Considered	02/17/07
--------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449A/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/663,407
				Filing Date	September 15, 2003
				First Named Inventor	Zavitz et al.
				Art Unit	1648
				Examiner Name	Unknown (ARROW), STRACK
Sheet	5	of	5	Attorney Docket Number	1907.04-1

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. T ²			
JK		SCHUBERT et al., "Proteasome inhibition interferes with Gag polyprotein processing, release, and maturation of HIV-1 and HIV-2", PNAS, November 21, 2000, 97(24):13057-13062.			
		SORKINA et al., "Clathrin, adaptors and eps15 in endosomes containing activated epidermal growth factor receptors", Journal of Cell Science, 1999, 112:317-327.			
		STRACK et al., "A role for ubiquitin ligase recruitment in retrovirus release", PNAS, November 21, 2000, 97(24):13063-13068.			
		VERKHIVKER, "Towards understanding the mechanisms of molecular recognition by computer simulations of ligand-protein interactions", Journal of Molecular Recognition, 1999, 12:371-389.			
		VERPLANK et al., "Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55Gag", PNAS, July 3, 2001, 98(14):7724-7729.			
		VOGTL., "Ubiquitin in retrovirus assembly: Actor or bystander?", PNAS, November 21, 2000, 97(24):12945-12947.			
		WHITTLE et al., "Protein Structure-Based Drug Design", Annu. Rev. Biophys. Biomol. Struct., 1994, 23:349-375.			
		YASUDA et al., "A Proline-Rich Motif (PPPY) in the Gag Polyprotein of Mason-Pfizer Monkey Virus Plays a Maturation-Independent Role in Virion Release", Journal of Virology, May 1998, 72(5):4095-4103.			
		YUAN et al., "Infectivity of Moloney Murine Leukemia Virus Defective in Late Assembly Events Is Restored by Late Assembly Domains of Other Retroviruses", Journal of Virology, August 2000, 74(16):7250-7260.			
		YUAN et al., "Mutations altering the Moloney murine leukemia virus p12 Gag protein affect virion production and early events of the virus life cycle", The EMBO Journal, 1999, 18(17):4700-4710.			
↓		ZHANG et al., "Drug Resistance during Indinavir Therapy Is Caused by Mutations in the Protease Gene and in Its Gag Substrate Cleavage Sites", Journal of Virology, September 1997, 71(9):6662-6670.			

Examiner Signature		Date Considered	62	17	07
--------------------	--	-----------------	----	----	----

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.